Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1876 to 1890 of 8973 results

  1. Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

    In development Reference number: GID-TA11023 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]

    Awaiting development Reference number: GID-TA10279 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]

    In development Reference number: GID-TA11749 Expected publication date:  10 June 2027

    Technology appraisal guidance
    In development

  4. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development Reference number: GID-TA11019 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development Reference number: GID-TA10911 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

    In development Reference number: GID-TA10832 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Upadacitinib for treating giant cell arteritis [ID6299]

    In development Reference number: GID-TA11330 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. DCVax-L for treating glioblastoma [ID836]

    In development Reference number: GID-TA10143 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Third molars (impacted) - prophylactic removal [ID898]

    In development Reference number: GID-TAG525 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6146]

    Awaiting development Reference number: GID-TA11222 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]

    Awaiting development Reference number: GID-TA11538 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Sotatercept for treating pulmonary arterial hypertension [ID6163]

    In development Reference number: GID-TA11103 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

    In development Reference number: GID-IPG10392 Expected publication date: TBC

    Interventional procedures guidance
    In development

  14. Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]

    In development Reference number: GID-TA11440 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation